1 the Motavizumab Cardiac Study Group Austria: U. Salzer-Muhar

Total Page:16

File Type:pdf, Size:1020Kb

1 the Motavizumab Cardiac Study Group Austria: U. Salzer-Muhar Feltes et al. – Supplemental Material The Motavizumab Cardiac Study Group Austria: U. Salzer-Muhar, Medical University of Vienna, Vienna; J. I. Stein, Medical University of Innsbruck, Innsbruck; G. Tulzer, General Hospital of Linz, Linz Belgium: A. Benatar, Academic Hospital, Free University of Brussels, Brussels; H. Dessy, Queen Fabiola Children's University Hospital, Brussels; D. De Wolf, Ghent University Hospital, Ghent; M. Gewillig, University Hospitals Leuven, Leuven; M. Massin, Regional Center Hospital Citadelle, Liege; T. Sluysmans, St. Luke’s Clinic Catholic University of Leuven, Brussels; B. Suys, Antwerp University Hospital, Edegem; P. Vandenberghe, Queen Paola Children’s Hospital, Antwerp Bulgaria: M. N. Bosheva, E. D. Ghenev, M. Krasteva, University Multiprofile Hospital for Active Treatment "St.Georgi", Plovdiv; P. Chakarova, Multiprofile Hospital for Active Treatment "Stara Zagora", Stara Zagora; S. Dachev, Regional Dispensary for Pulmonary Diseases with Inpatient sector-Ruse, Ruse; I. Galabov, Multiprofile Hospital for Active Treatment "St. Marina", Varna; A. Georgieva, Multiprofile Hospital for Active Treatment “Plovdiv”, Plovdiv; E. Hristova, Specialized Hospital for Active Treatment of Pediatric Diseases, Sofia; V. Nedkova-Kolarova, R. Rosmanova, University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski", Pleven; M.R. Tzonzarova, Specialized Hospital for Active Treatment of Cardiovascular Diseases, Sofia Canada: A. Kakadekar-Sankaran, K. Sankaran-Kakadekar, Royal University Hospital, Saskatoon; J. Langley, Clinical Trials Research Center, IWK Health Center, Halifax; M. Lebel, Sainte Justine Hospital, Montreal; K.-J. Lee, The Hospital for Sick Children, Toronto; J. McDonald, McGill University Health Centre, Montreal; J. Robinson, Stollery Children’s Hospital, University of Alberta, Edmonton; H. Rosenberg, Children’s Hospital of Eastern Ontario, Ottawa; A. Singh, Children and Women’s Hospital of British Columbia, Vancouver Czech Republic: J. Biolek, Most Hospital, Most; R. Brabec, Motol Teaching Hospital, Prague; M. Cihar, Na Bulovce Teaching Hospital, Prague; P. Jehlicka, Pilsen Teaching Hospital, Pilsen- Lochotin; Z. Kokstein, Hradec Kralove Teaching Hospital, Hradec Kralove; K. Liska, Prague General Teaching Hospital, Prague; Z. Stranak, The Institute for Care of Mother and Child, Prague Denmark: B. Windelborg Nielsen, Aarhus University Hospital, Skejby, Aarhus France: I. Denjoy, Robert Debre Hospital, Paris; E. Dumas de la Roque, Bordeaux Children's Hospital, Bordeaux; B. Escande, Hospital Hautpierre, Strasbourg; J.-M. Lupoglazoff, Marie Lannelongue Surgical Center, Le Plessis Robinson; F. Marcon, Subscribers’ Hospital, Vandoeuvre Les Nancy; P. Morville, American Memorial Hospital, Reims; D. Semama, University Hospital of Dijon, Dijon; U. Simeoni, Hospital of the Conception, Marseille Germany: R. Dalla Pozza, H. Netz, Ludwig Maximilian University Hospital, Munich; S. Dittrich, University Hospital of the Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; M. Hofbeck, Tübingen University Hospital, Tübingen; D. Kececioglu, Heart and 1 Feltes et al. – Supplemental Material Diabetes Center North Rhine-Westphalia, Bad Oeynhausen; M. F. Knuf, Johannes-Gutenberg University, Mainz; H.-H. Kramer, Schleswig Hostein University Hospital, Kiel; R. Motz, Oldenburg Hospital, Oldenburg; T. Paul, Georg-August University Gottingen, Gottingen; M. Peuster, Rostock University Hospital, Rostock, Ruhr University Bochum, Bad Oeynhausen; A. Wessel, Hannover Medical School, Hannover Hungary: K. Adamovich, University of Pecs, Pecs; L. Barkai, Borsod-Abaúj-Zemplén Megyei County Hospital and University Teaching Hospital, Miskolc; F. Dicso, Andrew Josa Teaching Hospital, Nyiregyhaza; M. Katona, University of Szeged, Szeged; A. Miklós, Petz Aladar County Teaching Hospital, Gyor; S. Miklós, Semmelweis University, Budapest; A. Nagy, University of Debrecen Medical and Health Center, Debrecen; E. Szabo, Csolnoky Ferenc Hospital, Veszprem; A. Szatmari, Gottsegen Gyorgy National Institute of Cardiology, Children’s Center, Budapest Israel: S. S. Ashkenazi, Schneider Children's Medical Center of Israel, Petach Tikva; A. Barzilai, The Chaim Sheba Medical Center, Tel Hashomer; I. Berger, F. B. Mimouni, Tel-Aviv Sourasky Medical Center, Tel Aviv; R. Dagan, Soroka University Medical Center, Beer Sheva; D. Engelhard, Hadassah University Hospital Ein Kerem, Jerusalem; I. Kassis, Rambam Medical Center, Haifa; Y. Schlesinger, Shaare Zedek Medical Center, Jerusalem; E. Somekh, Edith Wolfson Medical Center, Holon Lebanon: F. F. Bitar, American University of Beirut Medical Center, Beirut; L. Daou, Hotel Dieu De France, Beirut; R. Sacy, St. George University Hospital, Ashrafieh Poland: G. Dawid, Tadeusz Sokołowski Autonomous Public Clinical Hospital No. 1 of the Pomeranian Medical Academy, Szczecin; J. S. Gadzinowski, Gynecological-Maternity Hospital of the Medical University of Poznan, Poznan; G. Gornicka, Professor Anthony Gebali Children’s Clinical Hospital, Lublin; B. Kassur-Siemienska, Children’s Health Center Institute, Warsaw; A. Kojro-Wojcieszonek, K. Mackowska, Provincial Children's Hospital of Bydgoszcz, Bydgoszcz; P. Korbal, Dr. John Biziela Independent Public Health Hospital, Bydgoszcz; A. Sysa, Institute of Polish Mother’s Health Center, Lodz; M. Szczepanski, Independent Public Hospital of the Medical University of Bialystok, Bialystok; M. A. Wojtalik, Charles Jonschera Hospital of the University of the Medical Sciences, Poznan Russia: N. B. Baltserovich, City Outpatient Clinic #113, St. Petersburg; V. Bulatov, Kazan State Medical University, Kazan; A. N. Galustyan, St. Petersburg State Pediatric Medical Academy; K. V. Gorbatikov, Regional Clinical Hospital Tyumen, Tyumen; S. N. Ivanov, Research Cardiology Institute of Tomsk Scientific Center, Tomsk; V. G. Lyubomudrov, O. A. Solovieva, St. Petersburg City Children’s Hospital #1, St. Petersburg; S. A. Shadrin, Kuban State Medical Academy, Krasnodar; Y. S. Sinelnikov, Meshalkin Research Institute of Blood Circulation, Novosibirsk Spain: J. Casaldaliga, Vall d’Hebron University Hospital, Barcelona; J. F. Exposito, Maternal and Child Hospital Jaen, Jaen; I. Fernandez-Santamarina, Vigo General Hospital, Vigo; D. García de la Calzada, Miguel Servet University Hospital, Zaragoza; L. García-Guereta, Hospital La Paz, Madrid; J. M. Guia, The Virgin of Arrixaca University Hospital, El Palmar; J. M. 2 Feltes et al. – Supplemental Material Guzman Cabañas, Queen Sofia Hospital, Cordoba; M. A. Izquierdo, Donostia Hospital, San Sebastian; E. Maroto, Gregorio Maranon Hospital, Madrid; C. Medrano, Juan Canalejo Hospital, La Coruna; J. Ortiz, Jerez Hospital, Jerez de la Frontera; A. Perez, October 12 Hospital, Madrid; C. Planell, Josep Trueta Hospital, Girona; M. Rissech, St. Joan of God Hospital, Esplugas de Llobregat; M. D. Rodriguez, Virgin of the Snow University Hospital, Granada; J. Santos, Virgen del Rocio University Infant Hospital, Seville; A. Valls-i-Soler, Hospital of the Cross, Barakaldo; I. Zabala, Maternal and Infant Hospital, Malaga Sweden: A. Jonzon, Uppsala University Hospital, Uppsala; E. Pesonen, Lund University Hospital, Lund; J. Sunnegardh, Sahlgrenska University Hospital, Goteborg; P. Winberg, Karolinska University Hospital, Stockholm United Kingdom: M. Blackburn, Leeds General Infirmary, Leeds; F. A. Bu’Lock, University Hospitals of Leicester, Leicester; F. Casey, Royal Belfast Hospital for Sick Children, Belfast; P. Daubeney, Royal Brompton Hospital, London; B. Jani, Medway Maritime Hospital, Gillingham; M. J. Marsh, Southampton General Hospital, Southampton; R. Tulloh, Bristol Royal Hospital for Children, Bristol United States: M. Aouthmany, Mercy Children's Hospital, St. Vincent Mercy Medical Center, Toledo, OH; A. Arrieta, G. Goodman, Children's Hospital of Orange County, Orange, CA; A. Atz, Medical University of South Carolina, Charleston, SC; V. Balaraman, Kapiolani Medical Center for Women and Children, Honolulu, HI; J. Bolivar, Miami Children’s Hospital, Miami, FL; D. Bratcher, Children’s Mercy Hospital, Kansas City, MO; R. Breitbart, Children’s Hospital Boston, Boston, MA; J. Brenner, Johns Hopkins Hospital, Baltimore, MD; D. Burchfield, University of Florida School of Medicine, Shands Children's Hospital, Gainesville, FL; A. Cabalka, Mayo Clinic, Rochester, MN; M. Camitta, Duke University Medical Center, Durham, NC; K. Chintala, Children’s Hospital of Michigan, Detroit, MI; W. Covitz, Wake Forest University Health Sciences Center, Winston-Salem, NC; L. Cripe, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; P. Dennehy, Rhode Island Hospital, Providence , RI; J. Domachowske, SUNY Upstate Medical University, Syracuse, NY; K. Dooley, Children’s Healthcare of Atlanta, Atlanta, GA; J. Englund, Children;s Hospital and Regional Medical Center, Seattle, WA; R. Fedderly, Children’s Hospital of Wisconsin, Milwaukee, WI; T. Hoffman, Nationwide Children’s Hospital Research Institute, Columbus, OH; J. Fergie, Driscoll Children’s Hospital, Corpus Christi, TX; J. Finnigan, Children’s Cardiology Associates PLLC, Austin, TX; R. Fox, University of Maryland, Baltimore, MD; D. Freeman, Arkansas Pediatric Clinic, Little Rock, AR; A. Friedman, Yale New Haven Children’s Hospital, New Haven, CT; R. Gajarski, University of Michigan, Ann Arbor, MI; D. Gremmels, Children’s Hospital and Clinic, Minneapolis, MN; S. Gullquist, Virginia Commonwealth University Health System, Richmond, VA; C. Hall, University of Rochester, Rochester, NY; F. Henderson, University of
Recommended publications
  • Relics of the Bulgarian National Epic
    PAISStt OF HILENDAR: FOUNDER OF THE NATIONAL IDEOLOGY In modern historiography the first centuries of the of the respectful image of Mediaeval Bulgaria. In Sremski Ottoman rule of Bulgarian lands are determined as Late Karlovci, one of the most active literary centres of the Middle Ages. The time from the beginning of the 18th time, Paissi read the book of Dubrovnik Abbot Mavro century to the 1877-1878 Russo-Turkish War is called Orbini "The Realm of the Slavs" in which he discovered Bulgarian National Revival. If the National Revival period considerable evidence about the Bulgarians' past. for Northern Bulgaria and the Sofia Region continued by In 1762 he completed "Slav-Bulgarian History, about 1878, for Eastern Rumelia it was by 1885 and for the People and the Kings, the Bulgarian Saints and All Macedonia and Adrianople Thrace by 1912-1913. Bulgarian Activities and Events". In 83 hand-written The National Revival in the Bulgarian lands witnessed pages the inspired Hilendar Monk interpreted using considerable economic progress. The Bulgarian were romantic and heightened tone the grandour of increasingly getting rid of their mediaeval restricted out- Mediaeval Bulgaria, the victory of the Bulgarian army look and helplessness and were gradually getting aware over Byzantium, the impressive bravery and manliness of as people, aspiring towards economic and cultural the Bulgarians, the historic mission of the Cyril and progress. Hilendar monk Paissii became a mouthpiece of Methodius brothers and other eloquent facts, worthy to these changes in the national self-awareness. He was be remembers and respected by the successors. Already the first to perceive the beginning of the new time and in the forward this noted Bulgarian appealed with gen- the need of formulating verbally the maturing historical uine sincerity towards his compatriots to love and keep prospects and tasks before the Bulgarian people.
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]
  • “To Get Rid of Turks”. the South-Slavic States and Muslim Remigration in the Turn of 1870S and 1880S1
    “TO GET RID OF TURKS”. THE SOUTH-SLAVIC STATES AND MUSLIM REMIGRATION IN THE TURN OF 1870S AND 1880S1 Krzysztof Popek Jagiellonian University in Kraków, Institute of History ORCID ID: 0000-0001-5864-5264 Introduction The Great Eastern Crisis (1875–1878) led to migrations on an in- comparable scale in the Balkan Peninsula. The Russian-Turkish War of 1877–1878 forced about 350,000 Muslims to leave the Bulgarian lands, which we will understand as the area covering the Principality of Bulgaria and Eastern Rumelia. Sanjak of Niš’s occupation by the Serbian Army resulted in the exodus of 71,000 Muslims. After the situation in the region had stabilized, the refugees (so-called Muhajirs) wanted to get back to their homes in the newly created Principality of Bulgaria, autonomous Eastern Rumelia (first controlled by Russians and later by Bulgarians), and the lands annexed by Serbia. The return of war refugees was one of the central problems the South-Slavic states faced in the first years after the Great Eastern Cri- sis. It led to serious complications, which had various reasons. Among the most significant ones was the logistic deployment of the remigrants in the areas often settled by Bulgarians of Macedonia and Thrace, and by Serbians of Kosovo and Montenegro. Another one was diplomatic disputes between the Sublime Porte and the Great Powers, the latter 1 ����������������������������������������������������������������������������������������Research presented in this article was financed by the grant of the Polish National Sci- ence Center: The Balkan Migration Processes in the 19th Century. Cases of Bulgaria and Serbia (2017/25/N/HS3/00576).
    [Show full text]
  • LEONARDO PROJECT – English Summary the Project Main Goal Is
    Project national LLP-LdV/PAR/2011/RO//129 number Project title “Introducing standards of the best medical practice for the patients with inherited Alpha-1 Antitrypsin Deficiency in Central Eastern Europe” LEONARDO PROJECT – english summary The project main goal is to support development of Central Eastern European Network (CEE) for Alpha-1 Antytrypsin Deficiency (A1ATD) diagnostics and treatment that will function within AIR (Alpha One International Registry) European network of medical centers specializing in A1ATD. Parteners 1. The National Institute of Tuberculosis and Lung Diseases/ Poland (Coordinator) 2. Hannover Medical School/ Germany 3. Institute of Pneumophtysiology “Marius Nasta”/ Romania 4. PJ Safarik University, Faculty of Medicine/ Slovakia 5. Leiden University Medical Center h/o Academisch Ziekenhuis Leiden/ Netherlands 6. UMHAT “Dr.Georgi Stranski” Pleven EAD, Clinic for pneumonology and phthisiatry"/ Bulgaria 7. Vilnius University Faculty of Medicine/ Lithuania 8. Università degli Studi di Pavia/ Italy The project is designed to address specific CEE regional educational needs, therefore its aims are: • to develop individualized training program for respiratory professionals : physicians, physiotherapists, laboratory staff involved in A1ATD diagnostics and medical care in CEE; program will be tailored according to specific country needs • to develop educational materials for respiratory professionals in national CEE languages • to create awareness of A1ATD problem and patient needs in CEE • to promote A1ATD European network in CEE European countries Project Stages: Stage 1: Central Eastern European Network establishment: assessing local needs and potential to launch close cooperation both regionally as well as within the existing European network (AIR)- workshop Stage 2A: Training visits Stage 2B: Focus group workshops Stage 3A: European network AIR conference in Warsaw Stage 3B: Educational materials for respiratory professionals and dissemination of results .
    [Show full text]
  • L Shire 2020 Disclosure Report ENG 21 June.Xlsx
    Date of publication: 2021-06-21 HCPs: City of Principal Practice HCOs: city Unique country identifier Full Name Country of Principal Practice Principal Practice Address Contribution to costs of Events Fee for service and consultancy where registered OPTIONAL TOTAL Donations and Grants to HCOs Sponsorship agreements with HCOs / third parties Related expenses agreed in the fee for service or consultancy contract, OPTIONAL Registration Fees Travel & Accomodation Fees appointed by HCOs to manage an Event including travel & accomodation relevant to the contract INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) Atanas Banchev Sofia Bulgaria Byalo More 8 N/A N/A 1,706.00 1,706.00 Анна Валериева София Bulgaria ул.Св.Георги Софийски 1 N/A N/A 176.02 5,307.00 5,483.02 Даниела Мирчева Авджиева Тзавелла София Bulgaria ул.Свето Преображение 20 N/A N/A 1,024.00 1,024.00 Емил Паскалев София Bulgaria ул.Св.Георги Софийски 1 N/A N/A 1,173.00 1,173.00 HCPs Мария Тончева Стаевска Коташева София Bulgaria ул.Св.Георги Софийски 1 N/A N/A 176.02 1,227.00 1,403.02 Мила Жекова Байчева София Bulgaria бул.Акад.Иван Евстратиев Гешов 11 N/A N/A 352.05 352.05 OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons Aggregate amount attributable to transfers of value to such Recipients - Art.
    [Show full text]
  • Investbulgaria Agency
    InvestBulgaria Agency June 2014 InvestBulgaria Agency issue 6 (9), year 2 Economic News - Business, Investments, Trade Headlines from the European institutions Analysis of Sector Monthly Investment Opportunities of Municipality Electronic Publication Interview Chambers of Commerce in Bulgaria Macroeconomic Indicators Upcoming Events INVESTBULGARIA AGENCY TODAY WE PRESENT: Bulgarian Small and Medium Enterprises Promotion Agency Evgeni Ivanov Executive Director of the Bulgarian Small and Medium Enterprises Promotion Agency (BSMEPA) He graduated from the Technical University of Sofia, Electrical machines and apparatus. He has two Master's degrees - Economics, organization and management of patent law and licensing activity and Complex social and economic development of the urban economy. He is fluent in English and Russian. In his professional career he held the posts of Executive Director of Astera Jsc, Astera Holding Jsc, Sinel Jsc, Chairman of the Board of Directors of Aroma Jsc, member of the Management Board and the Supervisory Board of Aroma Jsc, member of the Commission for Protection of Competition. He was a Member of the 40th National Assembly, where he was a member of the Budget and Finance committee and Economic Policy committee. Until him taking the seat as CEO of BSMEPA, Evgeni Ivanov was Chairman of BNAEOPC (Bulgarian National Association Essential Oils, Perfumery and Cosmetics), board member of EcoBulpack and board member of the Union Made in Bulgaria. Small and Medium Enterprises Promotion Agency is an administrative structure of the Ministry of Economy and Energy and as such it implements the state policy to promote entrepreneurship development and internationalization of SMEs. The Agency is transmission between the state and small and medium-sized companies.
    [Show full text]
  • Summary INTERNAL DISEASES PLENARY LECTURE Summary
    Abstracts from Jubilee Scientific Conference “45 years Medical University – Pleven”, 31 Oct - 2 Nov, 2019 1Institute of Metal Science, Equipment INTERNAL DISEASES and Technologies with Hydro- and Aerodynamics Centrе, PLENARY LECTURE Bulgarian Academy of Sciences, Sofia, Bulgaria CARDIAC SARCOIDOSIS – A NOT SO Corresponding Author: RARE TYPE OF CARDIOMYOPATHY Stefan Valkov Institute of Electronics, WITH RHYTHM DISTURBANCES Bulgarian Academy of Sciences 72, Tsarigradsko Chaussee Blvd. Borislav B. Dinov Sofia, 1784 Bulgaria Heart Center University of Leipzig, e-mail: [email protected] Germany Summary Corresponding Author: Due to the combination of attractive mechanical Borislav B. Dinov properties, biocompatibility and resistance to Heart Center University of Leipzig corrosion, the Co-Cr based alloys are widely Strümpellstraße 39 used for manufacturing of dental joints, implants 04289 Leipzig Germany and other medical devices. However, some e-mail: [email protected] drawbacks related to low hardness and wear resistance can be mentioned. These limitations Summary depend mostly on the surface properties and Cardiac involvement can occur in patients can be overcome by an appropriate technology with pulmonary or systemic sarcoidosis with for surface manufacturing. In recent years, the varying symptoms and severity. It can mimic deposition of coatings has been widely used for virtually every type of cardiomyopathy and is improving the properties of the materials. There therefore frequently misdiagnosed. Even more exist some technologies for depositing thin challenging are the cases of isolated cardiac films and coatings, including physical vapour sarcoidosis which are considered rare, often deposition (PVD), chemical vapour deposition remain unrecognized and have grave prognosis if (CVD), among others. The direct current (DC) left untreated with immunosuppressive therapy.
    [Show full text]
  • The SOLID-TIMI 52 Randomized Clinical Trial
    Supplementary Online Content O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. doi:10.1001/jama.2014.11061 eAppendix 1. SOLID-TIMI 52 trial - Trial Leadership & Investigators eAppendix 2. Inclusion and Exclusion Criteria eAppendix 3. Clinical Endpoint Definitions eFigure 1. Cumulative Incidence Curves for the Secondary Endpoint CV Death, MI or Stroke eFigure 2. Subgroups of Interest for the Secondary Composite Endpoint of CV Death, MI or Stroke eTable. Summary of MI According to the Universal Classification of MI by Randomized Treatment Arm eReferences This supplementary material has been provided by the authors to give readers additional information about their work. © 2014 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 O’Donoghue et al., SOLID-TIMI 52 trial - Supplementary Appendix eAppendix 1. SOLID-TIMI 52 trial - Trial Leadership & Investigators SOLID-TIMI 52 Executive Steering Committee members Chair: Eugene Braunwald (TIMI Study Group, Brigham and Women’s Hospital, Boston, MA, US) Global Principal Investigator: Christopher P. Cannon (TIMI Study Group, Brigham and Women’s Hospital, Boston, MA, US) Members: Christoph Bode (Medizinische Universitatsklinik Abt. Innere Medizin III, Freiberg, Germany) Judith Hochman (New York University School of Medicine, New York, NY, US) Aldo P. Maggioni (AMNCO Research Center, Firenze, Italy) Ph. Gabriel Steg (INSERMU698,Hôpital Bichat-CI. Bernard, Paris, France) Patrick Serruys (Erasmus University, Rotterdam, Netherlands) Douglas Weaver (Henry Ford Heart & Vascular Institute, Detroit, MI, US) Harvey D. White (Auckland City Hospital, Auckland University, Auckland, New Zealand) GlaxoSmithKline members: Mary Ann Lukas (GlaxoSmithKline, Philadelphia, PA, US) Richard Y.
    [Show full text]
  • WAS HELD in the MEDICAL UNIVERSITY – PLEVEN Pleven Is the Second City to Take Part in the Preparation of Northwest Region Were Invited to Attend the Workshop
    Publication Academia on Ecology MEDICAMEDICA and Medicine ISSN - 1314 - 958X Vol .1 , (March - April ) 201 8 MU - Pleven’s Medical Newspaper / 1.00 lv. THE MEDICAL DOCTORS FROM CLASS 2018 115 HEALTHCARE SPECIALISTS GRADUATED OF THE FACULTY OF MEDICINE р. 2 FROM THE FACULTY OF PUBLIC HEALTH р. 2 HAVE OFFICIALLY GRADUATED р. 3 PROF. DR SLAVCHO TOMOV WAS ELECTED A MEMBER OF THE MANAGEMENT BOARD OF THE COUNCIL OF THE RECTORS SEMINAR ON THE р. 4 THE SOCIAL ACTIVITIES SPECIALTY "DEVELOPMENT AT THE MEDICAL COLLEGE - PLEVEN HELD A SCIENTIFIC FORUM TO OF REGIONAL CELEBRATE ITS 10-YEAR ANNIVERSARY SCIENTIFIC CENTERS" THE FACULTY OF HEALTH CARE AT MU-PLEVEN CELEBRATED WAS HELD IN THE th р. 3 THE 10 YEAR SINCE ITS CREATION MEDICAL UNIVERSITY – PLEVEN WITH A SCIENTIFIC FORUM р. 4 р. 3 MU-PLEVEN WILL HOST THE SECOND INTERNATIONAL HIFU CONFERENCE IN JUNE SUCCESSES OF MU-PLEVEN'S ALUMNI: THE TEAM OF PROF. GORCHEV PERFORMED A RARE AND COMPLEX OPERATION TO SAVE THE LIFE OF A PATIENT AND HER BABY - СТР. 11 UNIQUE ROBOT-ASSISTED OPERATION WAS CARRIED OUT BY A MULTIDISCIPLINARY TEAM OF SURGEONS IN PLEVEN - СТР. 13 DOCTORS FROM PLEVEN SAVED THE LIFE OF A YOUNG PATIENT BY EXTRACTING A HUGE TUMOR FROM HER OVARY - СТР. 14 AN UROLOGICAL TEAM FROM PLEVEN SAVES THE LIFE OF A PATIENT WITH THE USE OF A ROBOT-ASSISTED OPERATION - СТР. 15 IN PLEVEN, A UNIQUE FOR THE COUNTRY OPERATION OF A BRAIN TUMOR WAS CARRIED OUT WITH THE USE OF INTRAOPERATIVE NUCLEAR MAGNETIC RESONANCE - СТР. 18 Academia vol. 2 /201 8 MEDICA Graduation THE MEDICAL DOCTORS FROM CLASS 2018 OF THE FACULTY OF MEDICINE HAVE OFFICIALLY GRADUATED With a solemn ceremony held on Center for International Students.
    [Show full text]
  • Oct 2017 I ISSUE 20
    ISSN 2367-4717 I FREE GUIDE IN ENGLISH + MAP I Sept - Oct 2017 I ISSUE 20 BULGARIA IN BRIEF 1 2 BULGARIA IN BRIEF CITY INFO GUIDES .comfresh content 4 BULGARIA IN BRIEF 8 10 OVERVIEW 18 ACCOMMODATION 22 BARS AND RESTAURANTS 24 ENTERTAINMENT 26 CULTURE 17 36 USEFUL NUMBERS 26 PHILIPPUKRAINIAN NATIONAL KIRKOROV ACADEMIC OPERA WORLD TOUR 2017 28 36 USEFUL NUMBERS www.cityinfoguides.com BULGARIA IN BRIEF 3 fresh content 8 GRAB YOUR 17 FREE CITY GUIDE AND HAVE A NICE STAY PHILIPP KIRKOROV WORLD TOUR 2017 USEFUL NUMBERS www.cityinfoguides.com 4 BULGARIA IN BRIEF WELCOME TO BULGARIA Religion: Orthodox Average summer temperatures: 26° to 30°C Welcome to one of the oldest European states Average winter temperatures: -5° to 5°C with 6000-years old gold treasures, a center Time zone: GMT +2 of ancient civilizations, a country that hosts the Country dialing code: 00 359 sanctuary of the mystical singer Orpheus and Internet country code: .bg gave to the Slavonic people the Cyrillic alphabet. Capital: Sofia Bulgaria is the only one country in Europe Currency: Bulgarian Lev (BGN) that hasn’t changed its name since it was first established. The Bulgarian army has never lost a single flag in battle. The flag of Bulgaria is a HISTORY tricolor consisting of three equal-sized horizontal The Bulgarian state was founded circa 681 as bands of (from top to the bottom) white, green a union of the new-settled Proto-Bulgarians, of and red. It was first adopted after Russo-Turkish seven Slavonic tribes who have already settled War (1877-1878), where Bulgaria regained inde- this territory and with the inclusion of some pendence.
    [Show full text]
  • Application of Erection Hardness Score As a Diagnostic Tool to Assess Erectile Function Recovery After Robot-Assisted Radical Prostatectomy
    Volume 3- Issue 1: 2018 DOI: 10.26717/BJSTR.2018.03.000830 Boyan Stoykov . Biomed J Sci & Tech Res ISSN: 2574-1241 Mini Review Open Access Application of Erection Hardness Score as a Diagnostic Tool to Assess Erectile Function Recovery after Robot-Assisted Radical Prostatectomy Boyan A Stoykov*1, Nikolay H Kolev1, Vladislav R Dunev1, Pencho P Genov2 and Manish Sachdeva1 1Department of Urology, Medical University, Bulgaria 2Department of Urology, UMHAT Ruse, Bulgaria Received: February 26, 2018; Published: March 08, 2018 *Corresponding author: Boyan Stoykov, Clinic of Urology, Medical University Pleven, Bulgaria, Tel: ; Email: Abstract The objective of this study was to characterize time-dependent recovery of erectile function following robot-assisted radical prostatectomy (RARP) using the erection hardness score (EHS). This study included 42 patients with localized prostate cancer (PC) undergoing RARP without neoadjuvant hormonal therapy. The erectile function of each patient was assessed based on the international index of erectile function-5 (IIEF- 5) and EHS at the baseline and on every visit after RARP. In this series, potency was defined as the ability to have an erection sufficient for intercourse, corresponding to EHS ≥ 3, while patients with EHS ≥ 2 were regarded as those with erectile function. Of these 42 patients, 15 and 27 underwent bilateral and unilateral nerve-sparing procedures, respectively. A proportional increase in the IIEF-5 score according to EHS was noted at 12 months after RARP. At 3, 6 and 12 months after RARP, the recovery rates of erectile function were 22.6, 55.3 and 74.8 %, respectively, while those of potency were 11.7, 23.5 and 32.3 %, respectively.
    [Show full text]
  • A Randomized Clinical Trial
    Supplementary Online Content Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. Published online April 9, 2018. doi:10.1001/jamainternmed.2018.0397 eFigure. Study Overview eAppendix. Independent Ethics Committee or Institutional Review Board eTable 1. Hazard Ratios for Time to Occurrence of MACE and MACE+ eTable 2. Cardiovascular Deaths eTable 3. MACE and MACE+ Until End of Study Stratified by Baseline Framingham Cardiovascular Risk This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eFigure 1. Study Overview Treatment phase Non-treatment follow-up Extension non-treatment phase (EAGLES) (EAGLES) (EAGLES extension trial) Varenicline 1 mg twice daily EAGLES Bupropion baseline 150 mg twice daily randomization Screening NRT visit 21 mg/d patch with tapering Placebo EAGLES extension trial initiation visit Study visits (wk) 0 1 2 3 4 5 6 8 10 12 13 16 20 24 28 32 36 40 44 48 52 Study endpoint During treatment time intervals (wk) (EAGLES) During treatment and until 30 days’ follow-up (EAGLES) During treatment, 12 weeks’ follow-up and until end of study (EAGLES or EAGLES extension trial)* * End of study refers to last visit in the EAGLES extension trial, or in EAGLES for those subjects not enrolled into the EAGLES extension trial. © 2018 American Medical Association. All rights reserved. 2 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix.
    [Show full text]